Drug Trial Radar · NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
505
Planned (sponsor's estimate)
Start
Mar 4, 2020
Primary completion
Jul 28, 2030
Study completion Jul 29, 2032
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- BeiGene; BeOne (China only)
- First posted
- Jan 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10.2 (31 Aug 2026), only Parts 6 and 7 are open to accrual.
Conditions
- Prostate Cancer
Interventions
AMG 509Drug
AMG 509 administered as an IV infusion (Parts 1, 3, 4, 5, 6 and 7) or SC injection (Part 2).
AbirateroneDrug
Abiraterone administered as oral tablets.
EnzalutamideDrug
Enzalutamide administered as oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1-5 and 7: Incidence of Treatment-emergent Adverse EventsTime frame: 3 years
- Parts 1-5 and 7: Incidence of Treatment-related Adverse EventsTime frame: 3 years
- Parts 1-5 and 7 Dose Exploration Cohorts Only: Dose Limiting Toxicities (DLTs)Time frame: 28 days
- Parts 1-5 and 7: Number of Participants with Changes in Vital SignsTime frame: 3 years
- Parts 1-5 and 7: Number of Participants with Changes in Electrocardiogram (ECG) RecordsTime frame: 3 years
- Parts 1-5 and 7: Number of Participants with Changes in Clinical Laboratory Test ResultsTime frame: 3 years
- Part 6: Objective Response (OR) per RECIST v1.1Time frame: 3 years
Locations
54 sites in 10 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
Providence Saint Jude Medical Center
Fullerton, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Indiana University
Indianapolis, Indiana · Recruiting
Tulane Medical Center
Rochester, Minnesota · Completed
MidAmerica Cancer Care
Kansas City, Missouri · Recruiting
Washington University
St Louis, Missouri · Recruiting
Yale New Haven Hospital
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center Duke Cancer Center
Durham, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Terminated
Oncology Hematology Care Incorporated
Cincinnati, Ohio · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Prisma Health Upstate
Greenville, South Carolina · Completed
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Oncology Associates
Irving, Texas · Terminated
Intermountain Medical Center
Murray, Utah · Recruiting
Virginia Cancer Specialists PC
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Monash Medical Centre
Clayton, Victoria, Australia · Recruiting
Nanjing Drum Tower Hospital
Nanjing, China · Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Fudan University Shanghai Cancer Centre
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Provincial Peoples Hospital
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
Universitaetsklinikum Heidelberg
Heidelberg, Germany · Recruiting
Klinikum rechts der Isar der TUM
München, Germany · Recruiting
Universitaetsklinikum Muenster
Münster, Germany · Recruiting
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan · Recruiting
Yokohama City University Hospital
Yokohama, Kanagawa, Japan · Recruiting
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, Japan · Recruiting
Hospital da Luz, SA
Lisbon, Portugal · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.